Platinum

Generic Name: Platinum

Drug Type: Small Molecule

Chemical Formula: Pt

CAS Number: 7440-06-4

Unique Ingredient Identifier: 49DFR088MY

Background: Platinum is under investigation for the treatment of Metastatic Breast Cancer, Non-small Cell Lung Cancer, Gastric Large Cell Neuroendocrine Carcinoma, Colorectal Large Cell Neuroendocrine Carcinoma, and Pancreatic Large Cell Neuroendocrine Carcinoma, among others. Platinum has been investigated for the treatment and supportive care of Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Primary Cancer, Non Small Cell Lung Cancer, and Primary Peritoneal Carcinoma, among others.

Clinical Trials

Pembrolizumab + Platinum Doublets Without Radiation for Programmed Death-ligand 1 (PD-L1) ≥50% Locally Advanced NSCLC

Phase 2

Conditions: Locally Advanced Non-small Cell Lung Cancer

Interventions: Drug: Pembrolizumab
Drug: Cis Platinum
Drug: Carboplatin
Drug: Pemetrexed
Drug: nab paclitaxel

First Posted Date: 2019-11-06

Last Posted Date: 2019-11-06

Lead Sponsor: Kobe Minimally Invasive Cancer Center

Target Recruit Count: 21

Registration Number: NCT04153734

A Study of the Pan-immunotherapy in Patients With Relapsed/Refractory Ovarian Cancer

Phase 2

Completed

Conditions: Ovarian Cancer

Interventions: Drug: Manganese Chloride
Drug: nab-paclitaxel
Drug: Platinum chemotherapy
Drug: Sintilimab

First Posted Date: 2019-06-18

Last Posted Date: 2024-07-15

Lead Sponsor: Chinese PLA General Hospital

Target Recruit Count: 84

Registration Number: NCT03989336

Locations: 🇨🇳
Biotherapeutic Department of Chinese PLA General Hospital, Beijing, Beijing, China

Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients

Phase 2

Active, not recruiting

Conditions: Non-small Cell Lung Cancer
Hepatocellular Carcinoma
Head and Neck Squamous Cell Carcinoma

Interventions: Drug: cemiplimab
Drug: Platinum Doublet
Drug: fianlimab

First Posted Date: 2019-04-16

Last Posted Date: 2025-04-11

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 65

Registration Number: NCT03916627

Locations: 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States

Salvage Chemoradiation Therapy for Recurrence After Radical Surgery or Palliative Surgery in Esophageal Cancer Patients

Phase 3

Recruiting

Conditions: Esophageal Cancer

Interventions: Radiation: Involved field irradiation
Radiation: Elective field irradiation
Drug: Paclitaxel
Drug: Platinum
Drug: PEG-rhG-CSF

First Posted Date: 2018-11-06

Last Posted Date: 2018-12-12

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 300

Registration Number: NCT03731442

Locations: 🇨🇳
Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), Beijing, Beijing, China

Radiation and Chemotherapy With Ipilimumab Followed by Nivolumab for Patients With Stage III Unresectable Non-Small Cell Lung Cancer (NSCLC)

Phase 1

Terminated

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Radiation: Thoracic Radiotherapy
Drug: Nivolumab
Drug: Platinum Based Chemotherapy
Drug: ipilimumab

First Posted Date: 2018-09-10

Last Posted Date: 2023-02-15

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 19

Registration Number: NCT03663166

Locations: 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
🇺🇸
UNC Limeberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States
🇺🇸
Duke University, Durham, North Carolina, United States

Efficacy and Safety Evaluation of Sintilimab in Patients With Advanced or Metastatic Non-squamous NSCLC

Phase 3

Completed

Conditions: Lung Neoplasms

Interventions: Drug: Sintilimab
Drug: Pemetrexed
Drug: Platinum
Drug: Placebos

First Posted Date: 2018-07-31

Last Posted Date: 2023-02-27

Lead Sponsor: Innovent Biologics (Suzhou) Co. Ltd.

Target Recruit Count: 397

Registration Number: NCT03607539

Locations: 🇨🇳
Sun Yat-Sen University Cancer Center, Guangzhou, China

A Study of the Combination of Osimertinib, Platinum and Etoposide for Patients With Metastatic EGFR Mutant Lung Cancers

Phase 1

Active, not recruiting

Conditions: Lung Cancer

Interventions: Drug: Osimertinib
Drug: Platinum
Drug: Etoposide

First Posted Date: 2018-06-26

Last Posted Date: 2024-07-03

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 11

Registration Number: NCT03567642

Locations: 🇺🇸
Memorial Sloan Kettering Westchester, Harrison, New York, United States
🇺🇸
Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Commack, Commack, New York, United States

and more 3 locations